Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olaparib + elacestrant
- Development stage
- Unknown
- Lead developer
- Menarini
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Olaparib + elacestrant is a combination of two oral small molecule drugs used in oncology, particularly for the treatment of hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer with germline BRCA1/2 mutations. Olaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor that blocks DNA repair in cancer cells, leading to cell death—especially effective in tumors with BRCA mutations or homologous recombination deficiency[1][4][6]. Elacestrant is a selective estrogen receptor degrader (SERD), which binds to and degrades the estrogen receptor, thereby inhibiting estrogen-driven tumor growth[2][5][8]. The combination aims to address endocrine resistance and improve outcomes for patients with limited options after prior therapies.
- Other names
- olaparib + elacestrant
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)Pol II (RNA polymerase II elongation factors)ESR1 (ERα)Pol III (Dna-directed RNA polymerase III)
Beyond the preview
Go deeper on olaparib + elacestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olaparib + elacestrant.